Meningioma classification by immunohistochemistry: A replicability study.

ABSTRACT:

Introduction

Meningiomas account for nearly 40% of intracranial tumors. Recently, the immunohistochemistry (IHC) markers S100B, SCGN, ACADL and MCM2 have been shown to be associated with underlying biological subtypes of meningioma (MG1-MG4). We aimed to evaluate these IHC markers in a clinical setting.

Research question

Are the new proposed IHC markers clinically useful?

Methods

In total, 244 patients with meningiomas with tissue in TMAs were included and the IHC markers S100B, SCGN, ACADL and MCM2 were analyzed. Two sets of analyses were performed; the first included all samples with any staining considered positive, the second only samples with >10% immunopositivity. PFS and OS were analyzed in correlation to immunopositivity in the second analysis set.

Results<

SUBMITTER: Naslund O 

PROVIDER: S-EPMC9845417 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature